Adrenal Scans With Radioiodine-Labeled Norcholesterol (NP-59)
To investigate the feasibility of using NP-59 to localize adrenal tumors and assess their
functions under the influence of pharmacological manipulations.
Interventional
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
To investigate the feasibility of using NP-59 to localize adrenal tumors and assess their functions under the influence of pharmacological manipulations.
1 year
No
Neeta Pandit-Taskar, MD
Principal Investigator
Memorial Sloan-Kettering Cancer Center
United States: Food and Drug Administration
77-030
NCT00591643
July 1977
March 2011
Name | Location |
---|---|
Memorial Sloan-Kettering Cancer Center | New York, New York 10021 |